Colchicinoids from Colchicum Crocifolium Boiss.: A Case Study in Dereplication Strategies for (-)-Colchicine and Related Analogs Using LC-MS and LC-PDA Techniques by NC DOCKS at The University of North Carolina at Greensboro & Oberlies, Nicholas
Colchicinoids from Colchicum Crocifolium Boiss.: A Case Study in Dereplication 
Strategies for (-)-Colchicine and Related Analogs Using LC-MS and LC-PDA Techniques 
 
By: Feras Q. Alali, Ahmad Gharaibeh, Abdullah Ghawanmeh, Khaled Tawaha, and Nicholas H. 
Oberlies 
 
This is the peer reviewed version of the following article: 
 
Alali, F. Q., Gharaibeh, A. , Ghawanmeh, A. , Tawaha, K. and Oberlies, N. H. (2008), 
Colchicinoids from Colchicum crocifolium Boiss.: a case study in dereplication strategies for (–)‐
Colchicine and related analogues using LC‐MS and LC‐PDA techniques. Phytochemical 
Analysis, 19, 385-394. PMID: 18444231; doi: 10.1002/pca.1060 
 
which has been published in final form at https://doi.org/10.1002/pca.1060. This article may 
be used for non-commercial purposes in accordance with Wiley Terms and Conditions for 
Use of Self-Archived Versions. 
 
***© 2008 John Wiley & Sons, Ltd. Reprinted with permission. No further reproduction is 
authorized without written permission from Wiley. This version of the document is not the 





As a part of a project designed to investigate Colchicum species in Jordan, the chemical 
constituents of Colchicum crocifolium Boiss. (Colchicaceae) were investigated using LC‐MS and 
LC–UV/Vis PDA. A decision tree for working with colchicinods has been developed by 
incorporating data from LC‐UV/PDA and LC‐MS. This dereplication strategy draws upon the 
UV/PDA spectra to classify compounds into one of four structural groups and combines this with 
retention time and mass spectra/molecular weight to identify the compounds. This strategy was 
applied on a small amount of extract (2 mg) of Colchicum crocifolium to dereplicate 10 known 
compounds from four different structural groups, namely (−)‐demecolcine, 2‐demethyl‐(−)‐
colchicine or3‐demethyl‐(−)‐colchicine, N‐deacetyl‐(−)‐colchicine, (−)‐colchiciline, (−)‐
colchicine, β‐lumidemecolcine, 2‐demethyl‐β‐lumicolchicine or 3‐demethyl‐β‐
lumicolchicine, N,N‐dimethyl‐N‐deacetyl‐β‐lumicornigerine, (−)‐isoandrocymbine and (−)‐
autumnaline. Furthermore, a new compound was identi?ed as N,N‐dimethyl‐N‐deacetyl‐(−)‐
cornigerine. Three compounds, which had molecular ions at m/z 325, 340 and 374, could not be 
dereplicated into any obvious structural classes that have been isolated in our laboratories 
previously or reported in the literature.  
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To expedite discovery of new bioactive natural products from plant sources, it is of great 
importance to be able to discriminate between previously isolated, known compounds and new 
compounds, particularly at the level of the crude extract. This process, which is termed 
dereplication, is critical for the efficient use of valuable, and often scant, human and financial 
resources; science is not served by the reinvention of the proverbial wheel. By doing so, one can 
avoid the tedious isolation of known constituents, and thus focus on the targeted isolation of 
constituents presenting novel or unusual spectroscopic features (Hostettmann et al., 2001; 
Wolfender et al., 2006). 
 
Several hyphenated techniques are finding growing use in dereplication strategies. Traditionally, 
UV, MS and NMR spectroscopy are used separately for structure elucidation of pure natural 
compounds. However, the integration of all these techniques in their hyphenated forms, liquid 
chromatography–ultraviolet photodiode array detection (LC-UV/PDA), liquid chromatography–
mass spectrometry (LC-MS), liquid chromatography–nuclear magnetic resonance (LC-NMR) 
and liquid chromatography–nuclear magnetic resonance–mass spectrometry (LC-NMR-MS), 
may enable the complete characterisation of discrete compounds in mixtures in a single linear 
run of coupled analyses. In essence, hyphenated techniques can be defined as the coupling of 
HPLC separation technologies with on-line spectroscopic/spectrometric detection technologies 
(Wolfender et al., 2003, 2006). The extraordinary improvements in hyphenated analytical 
methods over the past two decades have broadened their applications in the analyses of 
biomaterials significantly, especially natural products. Several hyphenated techniques are used 
complementarily as powerful and economical tools for dereplication of natural products in crude 
plant extracts. They are able to give sufficient information to identify known components or, in 
the case of LC–NMR, full structural elucidation of unknown compounds. The combined use of 
these hyphenated techniques is also very useful for the on-line structure determination of 
compounds that are not separable at the preparative level and for the study of labile constituents. 
Moreover, they are very efficient for the recording of spectra in crude reaction mixtures at the 
microgram level, often enabling the determination, using Mosher’s esters, of absolute 
configurations on-line (Queiroz et al., 2003). Hyphenated techniques are also being used in 
related fields, such as chemotaxonomic studies, chemical fingerprinting, quality control of herbal 
products and metabolic studies (Wolfender et al., 2003; Yang, 2006). In short, the impact of 
hyphenated techniques in many forms of analytical chemistry is tremendous and cannot be 
overlooked, especially for the natural product chemist (Stobiecki, 2001). 
 
In our ongoing research on plants native to the Hashemite Kingdom of Jordan (Jordan), we have 
isolated and identified colchicine and more than 30 related analogues from different species of 
Colchicum. (−)-Colchicine (I) is one of the most well studied natural compounds, as it was first 
isolated in 1820 by Pelletier and Caventou (Pelletier and Caventou, 1820). It is still used as a 
pharmaceutical for the treatment of gout (Terkeltaub, 2003) and in a number of proinflammatory 
disorders, such as familial Mediterranean fever (Drenth and Meer, 2001) and Behcet’s disease 
(Sakane and Takeno, 2000). (−)-Colchicine (I) was found to possess potent antitumour activity 
in clinical investigations. However, its use as an antineoplastic agent is limited due to lack of 
tumour selectivity and high toxicity (Eigsti and Dustin, 1955). However, its promising potency 
encouraged medicinal and organic chemists to synthesise hundreds of colchicine analogues in an 
attempt to reduce toxicity and to refine the structure–activity relationships (Bergemann et al., 
2003; Cifuentes et al., 2006; Nakagawa-Goto et al., 2005). Among (−)-colchicine analogues, 
(−)-demecolcine is used for the treatment of myelocytic leukaemia and malignant lymphoma 
(Samuelsson, 1992). (−)-Colchicine is also used in biological and breeding studies to produce 
polyploidy, or multiplication of the chromosomes in the cell nucleus (Trease and Evans, 1989). 
Thus, although this compound was first described nearly two centuries ago, it and related 
analogues are still used today both as medicinal agents and as laboratory tools. As such, new 




Scheme 1 (−)-Colchicine (I). 
 
At least nine species of Colchicum are endemic to the unique biodiversity of Jordan, especially 
the desert environments, namely C. brachyphyllum Boiss. & Haussk. ex Boiss., C. crocifolium 
Boiss., C. hierosolymitanum Feinbr., C. ritchii. R. Br., C. schimperi Janka, C. stevenii Kunth, C. 
tauri Siehe ex Stef., C. triphyllum Kunze and C. tunicatum Feinbr (Al-Eisawi, 1998; Feinbrun- 
Dothan, 1986). A long-term goal of our research programme has been to study all of these, both 
in pursuit of new pharmaceutical leads and to investigate the rich, unique and under explored 
biodiversity of Jordan. To date five species have been investigated, resulting in several 
publications where new colchicine analogues have been described, including one with a novel 
ring system (Alali et al., 2005), and/or the profile of known colchicine analogues has been 
documented (Alali and El-Alali, 2005; Alali et al., 2005, 2006a–d; Al-Mahmoud et al., 2006). 
Moreover, to the best of our knowledge, eight of these nine species have not been analysed 
previously for bioactive phytochemicals prior to the initiation of our research. These 
investigations impart our team with valuable experience in colchicinoid chemistry, particularly 
spectroscopic/spectrometric and chromatographic properties. To expedite future efforts and to 
leverage this growing library of compounds and broad expertise in structural identification, it 
was desirable to develop dereplication procedures that would both (1) quickly identify and 
catalogue known colchicinoids and (2) focus efforts on structurally unique constituents. 
 
As a proof-of-principle study on dereplication strategies for colchicinoids, Colchicum 
crocifolium Boiss. (Colchicaceae) was investigated. Having no previous studies reported in the 
literature, the goal was the development of dereplication procedures that could quickly identify 
known compounds and classify unknowns into broad structural categories. From the alkaloid 
rich fraction of the whole plant (corms, leaves, stems and seeds), one new (12) and 10 known (1–
8, 11 and 13) compounds were identified, which can be classified into four structural classes: 
colchicine-like alkaloids—(−)-demecolcine (3), 2-demethyl-(−)-colchicine or 3-demethyl-(−)-
colchicine (4), N-deacetyl-(−)-colchicine (5), (−)-colchiciline (6), (−)-colchicine (7) and 
N,Ndimethyl-N-deacetyl-(−)-cornigerine (12); photoisomers of colchicine-type alkaloids—β-
lumidemecolcine (8), 2-demethyl-β-lumicolchicine or 3-demethyl-β-lumicolchicine (11), and 
N,N-dimethyl-N-deacetyl-β-lumicornigerine (13); androcymbine-type alkaloids—(−)-
isoandrocymbine (1); and phenethyltetrahydroisoquinoline-type alkaloids—(−)-autumnaline (2). 
This has led to the development of a decision tree that can be implemented even at the level of 
the crude extract to dereplicate known compounds and at least classify the major structural 




Plant material. Colchicum crocifolium flowers from March to April in the northeastern desert of 
Jordan, usually in clayey/sandy desert soils, and it is characterized as perennial herb with corms 
covered by thick, dark brown to reddish scales (Al-Eisawi, 1998). Corms, leaves, stems and 
seeds of C. crocifolium were collected during the seeding stage in April of 2005 and 2006 in the 
northeastern part of Jordan from Ar-Rwaished (elev. 691 m, lat. 32°33.465’N, long. 
38°16.854’E). The collected materials were identified by one of the authors (K.T.). A voucher 
specimen (PHC# 110) was deposited in the herbarium of the Faculty of Pharmacy, Jordan 
University of Science and Technology, Irbid, Jordan. The plant raw material was cleaned and 
air-dried at room temperature with the corms sliced into small pieces to speed up the process. 
The plant material (corms, leaves, stems and seeds) were mixed together and then ground to a 
fine powder using a laboratory mill, RetschMühle (RETSCH GmbH, Haan, Germany), passed 
through a 24 mesh sieve to generate a homogeneous powder, stored at room temperature (22–
23°C), and protected from light until required for analyses. 
 
Extraction and isolation. Dried plant material (537.7 g) was extracted with MeOH in a 
Soxhhlet apparatus for 3 h. The solvent was evaporated under reduced pressure to yield a 
MeOH-extract (148.1 g), which was fractionated based on the method of Simánek and coworkers 
(Santavy et al., 1981; Sutlupinar et al., 1988). Briefly, the MeOH-extract was dissolved in 5% 
acetic acid and extracted with light petroleum (fraction A; 12.0 g), after which the aqueous acid 
residue was re-extracted three times with diethyl ether (fraction B; 1.15 g). The acidic aqueous 
residues were made alkaline (pH 9) with 10% NH4OH followed by extraction three times with 
CH2Cl2 (fraction C; 1.94 g). The aqueous residues were then adjusted to pH 12 with 10% NaOH, 
and then extracted three times with diethyl ether (fraction D; 0.05 g), and finally three times with 
CH2Cl2 (fraction E; 0.1 g). All fractions were dried in vacuo. For the dereplication studies, an 
aliquot of fraction C (2 mg) was dissolved in mobile phase, filtered through a 0.45 μm Teflon 
filter, and then transferred to 2 mL amber HPLC vials. A 100 μL aliquot was injected onto the 
LC-UV/PDA and LC-MS systems. (−)-Colchicine standard (Fluka Chemie AG, Buchs) was used 
for method development and retention time matching. 
 
Liquid chromatography–mass spectrometry. LC-MS utilised an Agilant® (Palo Alto, CA, 
USA) ion-trap LC/MS coupled with APCI positive ionisation mode and an Agilant® 100 series 
HPLC equipped with a Hypersil BDS (125 × 4 mm; 5 μm) column (Thermo Electron, 
Auchtermuchty, UK). The mobile phase used H2O acidified with 0.1% formic acid (A) and 
MeOH (B) in the following gradient combinations: 0–2 min, 90% A; 2–27 min, 10% A; 27–30 
min 90% A. 
 
The mass detector conditions were as follows: APCI positive-ionisation mode, full-scan mode 
from 50 to 800 m/z, capillary voltage set at −4500 V, APCI temperature 400°C, gas flow-rate 4 
L/min. The mobile phase flow-rate was 1 mL/min with an injection volume of 100 μL. 
 
LC-UV/PDA. UV–vis PDA spectra were obtained on a Lachrom® Merck-Hitachi (Tokyo, 
Japan) HPLC, equipped with quaternary gradient L-7150 pump, L-7455 Diode-Array Detector, 
L-7200 auto-sampler and D-7000 Interface in the range between 200 and 400 nm. Mobile phase, 
flow rate, analytical column, injection volume and run times were the same as those used for LC-
MS. 
 
NMR. For the new compound (12), 1H and 13C-NMR spectra were recorded using a 400 MHz 
Bruker spectrometer (Switzerland), at the Faculty of Pharmacy, JUST, Jordan. 
 
RESULTS AND DISCUSSION 
 
The general dereplication strategy used a three-step approach. First, LC-MS was used to acquire 
the molecular ion and hence the molecular weight of the compound. These data were searched 
across natural product databases, particularly the Dictionary of Natural Products (Chapman & 
Hall, version 15:2), typically narrowing the search as much as possible by using the molecular 
weight to the first decimal place. This information was cross referenced against our compiled 
library, which has been constructed by gathering all spectral data reported in the literature for 
compounds isolated and characterised from Colchicum and related genera. Next, LC-UV/PDA 
was used to acquire the UV–vis spectra of a compound, and this fingerprint was used to group 
each compound into one of four structural classes that are typical for colchicine analogues 
(Rosso and Zuccaro, 1998; Shamma, 1972). Finally, the mass fragmentation data and the 
chromatographic retention times (and hence, relative polarity) were used to identify the 
structures of the compounds. Where possible, authentic reference standards were used to verify 
these assignments. By using this integrated approach, 10 known compounds were dereplicated 
rapidly, one new structure was identified and three compounds were grouped into complete 
unknowns (although structurally related to each other). 
 
 
Figure 1. (+)-APCI TIC chromatogram of the alkaloid rich fraction of C. crocifolium. 
 
For LC-MS and LC-UV/PDA analyses, the optimum separation conditions for the alkaloid-rich 
fraction (fraction C) of C. crocifolium were determined as outlined in the Experimental. Figure 1 
shows a typical LC-MS total ion chromatogram (TIC) of C. crocifolium, and this gave enough 
resolution that data from distinct compounds could be acquired. The mass fragmentation patterns 
for each peak are shown in Fig. 2, and Table 1 summarizes the retention times, UVmax (nm), and 
mass spectral data of each peak as well. In general, data obtained from LC-MS, using 
atmospheric pressure chemical ionisation (+)-APCI as the ionisation interface, were 
complementary to those obtained using LC-UV/PDA, hence enabling dereplication of colchicine 
and 10 related compounds in C. crocifolium. 
 
 
Figure 2. (+)-APCI Mass fragmentation patterns of the TIC chromatographic peaks of C. 
crocifolium. 
 
The strategy used in identifying these compounds was integrative in nature. Based on retention 
times (polarity), UV max (nm) pattern, mass spectral data (base peak and fragments), authentic 
standards of key colchicinoids, our long experience in Colchicum chemical constituents and 
general background in natural products biosynthesis, 14 compounds were tentatively identified in 
the (+)-APCI TIC chromatogram (1–14; Fig. 1). The chemical structures of one new (12) and 10 
known (1–8, 11 and 13) compounds were identified. Of these, six (3–7 and 12) were colchicine 
or colchicinelike compounds, three were lumiderivatives (photoisomers) (8, 11 and 13), one was 
an androcymbine-type (1) alkaloid, and one was a phenethyltetrahydroisoquinolinetype (2) 
alkaloid. Figure 3 show typical UV/PDA spectra of the general classes of Colchicum alkaloids 
that were detected in the investigated species (Rosso and Zuccaro, 1998; Shamma, 1972). 
UV/PDA spectra were very informative in determining the general structural class for each 
compound; even just by eye, the general patterns are quite characteristic. In the TIC from LCMS 
the following molecular ions m/z were observed: 371 (11.8, 14.7 and 17.7 min), 373 (13.5 and 
19.2 min), 385 (15.0 and 20.0 min), 358 (15.8 min), 416 (16.5 min), 400 (17.1 min), 340 (19.5 




Figure 3. Typical UV/PDA spectra of general classes of Colchicum alkaloids. 
Peak no. tR (min) UVmax (nm) LC-(+)-APCI mass fragments (m/z) Compound 
1 11.8 230, 260, 290 372 (M + H)+, 341, 214 
 
(−)-Isoandrocymbine 
2 13.5 225, 285 374 (M + H)+, 358, 341, 214 
 
(−)-Autumnaline 
3 14.7 247, 350 372 (M + H)+, 360, 358 
 
(−)-Dernecolcine 





Peak no. tR (min) UVmax (nm) LC-(+)-APCI mass fragments (m/z) Compound 
5 15.8 248, 350 358 (M + H)+, 357, 345, 327 
 
N-deacetyl-(−)-colchicine 
6 16.5 244, 350 416 (M + H)+, 387, 386, 358 
 
(−)-Colchiciline 
7 17.1 248, 348 400 (M + H)+, 383, 373, 358 
 
(−)-Colchicine 
8 17.7 228, 266 372 (M + H)+, 358, 341 
 
P-Lumidemecolcine 
9 19.2 230, 270 374, 372, 358, 341 Unknown 
10 19.2 244, 280 340, 372, 356, 340 Unknown 
11 20.0 230, 266 386 (M + H)+, 372, 355, 192 
 
2-Demethyl-β-lumicolchicine or 
Peak no. tR (min) UVmax (nm) LC-(+)-APCI mass fragments (m/z) Compound 
 
3- Demethyl-β-lumicolchicine 
12 20.9 244, 358 370 (M + H)+, 369, 358, 343 
 
N,N-Dimethyl-N-deacetyl(−)-comigerine 
13    
 
N,N -Dimethyl-N-deacetyl-β-Lumi-(−)-cornigerine 
14 23.0 240 325, 314, 313 Unknown 
 
The UV spectra of compounds 3, 4, 5, 6, 7 and 12 revealed the presence of absorption maxima at 
~350 nm, suggesting the presence of the O-methyl tropolone system characteristic of (−)-
colchicine and structurally related colchicinoids (Rosso and Zuccaro, 1998; Shamma, 1972). In 
general the (+)-APCI mass fragments, being few and with low intensity, were not always 
structurally informative as one might expect from this ‘soft’ ionisation technique. However, the 
molecular ion could be identified, which facilitated the literature cross referencing component. 
 
The (+)-APCI mass spectrum of (−)-colchicine (peak 7, tR = 17.1 min) showed a parent 
molecular ion at m/z 400 [M + H]+, and [M + H − COCH2]+ gave a peak at m/z 358. The 
UV/PDA spectrum of (−)-colchicine showed two absorption maxima at 248 and 348 nm, typical 
values for (−)-colchicine, supporting the identity of this compound (O’Neil et al., 2001; Rosso 
and Zuccaro, 1998). This was verified by comparison of the APCI mass spectrum, UV/PDA 
spectrum and HPLC retention time of an authentic standard of (−)-colchicine, where complete 
matching was observed (Alali et al., 2005). 
 
The (+)-APCI mass spectrum of peak 3 (tR = 14.7 min) showed a parent molecular ion at m/z 372 
for [M + H]+, 28 Da less than the analogueous peak in (−)-colchicine; it was also at an earlier 
retention time (i.e. more polar) than (−)-colchicine. The few and low-intensity mass fragments of 
this compound were not diagnostic. The UV/PDA spectrum of the compound showed two 
absorption maxima at 247 and 350 nm, implying structural similarities to (−)-colchicine. These 
data suggested that this compound was (−)-demecolcine (Freyer et al., 1987), and this was 
verified by comparison of the retention time and UV/PDA spectrum with that of (−)-
demecolcine, which was isolated previously in our laboratory (Alali et al., 2005). 
 
The (+)-APCI mass spectrum of peak 4 (tR = 15.0 min) showed a parent molecular ion at m/z 386 
for [M + H]+, 14 Da less than the analogueous peak in (−)-colchicine; it was also at an earlier 
retention time (i.e. more polar) than (−)-colchicine. The UV/PDA spectrum of the compound 
showed two absorption maxima at 243 and 353 nm, similar to colchicine-type alkaloids. These 
data suggested that this compound was either (−)-2- demethyl-(−)-colchicine or (−)-3-demethyl-
(−)-colchicine (Chommadov et al., 1990). Both (−)-2-demethyl-(−)- colchicine and (−)-3-
demethyl-(−)-colchicine were isolated previously in our laboratory (Alali et al., 2005; Alali et 
al., 2006a, d; Al-Mahmoud et al., 2006). The retention time and UV/PDA spectrum of this 
compound matched well with both of the above compounds, and due to their close structural 
similarities, 2D-NMR data are required to confirm its identity completely. Nevertheless, this 
dereplication strategy narrowed it to two possibilities. 
 
The (+)-APCI mass spectrum of peak 5 (tR = 15.8 min) showed a parent molecular ion at m/z 358 
for [M + H]+, 42 Da less than (−)-colchicine and 14 Da less than (−)-demecolcine. It is more 
polar than (−)-colchicine and less polar than (−)-demecolcine. A peak at m/z 326 suggests [M + 
H − CH3OH]+. The UV/PDA spectrum of the compound showed two absorption maxima at 248 
and 350 nm, similar to colchicine-type alkaloids. These data suggested that this compound was 
N-deacetyl-(−)-colchicine (Cordell et al., 1989). 
 
The (+)-APCI mass spectrum of peak 6 (tR = 16.5 min) showed a parent molecular ion at m/z 416 
for [M + H]+, 16 Da more than the analogueous peak of (−)-colchicine, and it was more polar 
than (−)-colchicine based on the retention time. A peak at m/z 358 suggests [M + H − 
NHCOCH3]+. The UV/PDA spectrum of the compound showed two absorption maxima at 244 
and 350 nm, similar to colchicine-type alkaloids. These data suggested that this compound was 
(−)-colchiciline (Potesilova et al., 1977). 
 
The (+)-APCI mass spectrum of peak 1 (tR = 11.8 min) showed a parent molecular ion at m/z 372 
for [M + H]+. The UV/PDA spectrum of the compound differs significantly from that of 
colchicine-type alkaloids. It showed three absorption maxima at 230, 260 and 290 nm, similar to 
androcymbine-type alkaloids (Freyer et al., 1987). The early retention time of this compound is 
also characteristic for this class of compounds. These data suggested that this compound was 
isoandrocymbine, a compound that was isolated previously in our laboratory (Al-Mahmoud et 
al., 2006). 
 
The (+)-APCI mass spectrum of peak 2 (tR = 13.5 min) showed a parent molecular ion at m/z 374 
for [M + H]+. Peaks at m/z 341 and 359 suggested [M − CH3OH]+ and [M + H − CH3]+, 
respectively. The UV/PDA spectrum of the compound differs from that of colchicine-type 
alkaloids, as it showed two absorption maxima at 225 and 285 nm, indicating the presence of a 
non-conjugated benzene chromophore, which are typical of phenethyltetrahydroisoquinoline-
type alkaloids (Shamma, 1972). The early retention time of this compound is also characteristic 
of this class of compounds. These data suggested that this compound was (−)-autumnaline 
(Freyer et al., 1987). 
 
The (+)-APCI mass spectrum of peak 8 (tR = 17.7 min) showed a parent molecular ion at m/z 372 
for [M + H]+, which was the same molecular weight as (−)-demecolcine. Peaks at m/z 341 and 
357 suggested [M + H − OCH3]+ and [M + H − CH3]+, respectively. The UV/PDA spectrum of 
the compound showed two absorption maxima at 228 and 266 nm, indicating that this compound 
was a photoisomer of (−)-demecolcine. The extended conjugation of (−)-demecolcine was 
interrupted upon isomerization to lumidemecolcine, and thus a shift of the absorption maxima to 
shorter wavelengths was observed at 228 and 266 nm compared with 247 and 350 nm in (−)-
demecolcine. These data suggested that this compound is β-lumidemecolcine (Chommadov et 
al., 1990). 
 
The (+)-APCI mass spectrum of peak 11 (tR = 20.0 min) showed a parent molecular ion at m/z 
386 for [M + H]+, which was the same molecular weight as 2-demethyl- or 3-demethly-(−)-
colchicine. The few and small-intensity fragments of this compound were not very informative. 
However, the UV/PDA spectrum of the compound showed two absorption maxima at 230 and 
266 nm, indicating that this compound was a photoisomer of 2-demethyl- or 3-demethly-(−)-
colchicine. These data suggested that this compound was either 2-demethyl-β-lumicholchicine or 
3-demethyl-β-lumicholchicine (Chommadov et al., 1990). As with peak 4 described above, this 
dereplication strategy quickly narrowed the structure to two possibilities. 
 
The (+)-APCI mass spectrum of peak 12 (tR = 20.9 min) and peak 13 (tR = 21.7 min) showed 
parent molecular ions at m/z 370 and 370, respectively for [M + H]+. The UV/PDA spectra of the 
two compounds were different. The former showed two absorption maxima at 244 and 358 nm, 
characteristic of colchicine-type alkaloids, while the later showed two absorption maxima at 238 
and 270 nm, characteristic of colchicine-type photoisomers. Judging from their close retention 
times on the relatively low polar side of the chromatogram, and from their mass fragments and 
PDA patterns, compound 13 was presumed to be a photoisomer of 12. Thus, compound 12 was 
determined to be a structurally new compound N,N-dimethyl-N-deacetyl-(−)-cornigerine and 
compound 13 was the known photoisomer of it, N,Ndimethyl-N-deacetyl-β-lumicornigerine 
(Potesilova et al., 1985). Indeed, as a continuation of this work, N,Ndimethyl-N-deacetyl-(−)-
cornigerine was isolated and purified for full spectral characterisation and biological evaluation, 
which will be the subject of a forthcoming publication. The 1H and 13C-NMR data for compound 
(12) are as follows: 1H NMR (400 MHz, CDCl3)—1.70 (1H, m, H-6), 2.09 [6H, s, N(CH3)2], 
2.19 (1H, m, H-6), 2.21 (1H, m, H-5), 2.40 (1H, m, H-5), 2.68 (1H, dd, J = 6, 6 Hz, H-7), 3.84 
(3H, s, 1-OMe), 3.98 (3H, s, 10-OMe), 6.01 (2H, d, J = 13 Hz, O-CH2-O), 6.43 (1H, s, H-4), 
6.80 (1H, d, J = 10.5 Hz, H-11), 7.17 (1H, d, J = 10.5 Hz, H-12), 8.07 (1H, s, H-8). 13C NMR 
(125 MHz, CDCl3)—30.3 (CH2, C-5), 36.4 (CH2, C-6), 43.5 N(CH3)2, 56.1 (CH3, 10-OCH3), 
59.9 (CH3, 1-OCH3), 68.2 (CH, C-7), 101.2 (CH2, O-CH2-O), 103.2 (CH, C-4), 111.6 (CH, C-
11), 125.1 (C, C-12b), 133.5 (CH, C-8), 134.03 (C, C-4a), 134.08 (CH, C-12), 136.5 (C, C-12a), 
137.3 (C, C-2), 140.1 (C, C-1), 148.7 (C, C-7a), 152.3 (C, C-3), 163.9 (C, C-10), 180.0 (C, C-9). 
In our previous studies on Colchicum species, we have not isolated previously compounds 1, 2, 
5, 6, 8, 11 and 13. 
 
We were unable to suggest chemical structures for compounds 9, 10 and 14, which had 
molecular ions at m/z at 374, 340 and 325, respectively for [M + H]+. Their UV/PDA spectra did 
not fit to any of the four major classes studied, and a search of the Dictionary of Natural 
Products did not reveal any obvious candidates. 
 
In short, a decision tree for working with colchicinoids has been developed by incorporating data 
from LC-UV/PDA and LC-MS. This dereplication strategy draws upon the UV/PDA spectra to 
classify compounds into one of four structural groups and combines this with retention time and 
mass spectra/molecular weight to identify the compounds, at least tentatively. This decision tree 
was used on a small amount of extract (2 mg) of Colchicum crocifolium to dereplicate 10 known 
compounds from four different structural groups. Furthermore, we identified one compound as 
having a new structure that may be N,N-dimethyl-N-deacetyl-(−)-cornigerine (12) and which is 
related to the known photoisomer, N,N-dimethyl-N-deacetyl-β-lumicornigerine (13). 
Importantly, three compounds could not be dereplicated into any obvious structural class that has 
been isolated in our laboratories previously or reported in the literature. The decision tree has 
thus focused our ongoing studies, both to verify the structure of the presumed new compound 
(12) and to further classify and identify the three unknowns (9, 10 and 14). 
 
From a broader scientific perspective, we have developed a strategy to speed the discovery of 
new compounds from crude alkaloid extracts. The described methods can be applied to the 
isolation/dereplication of other related classes of alkaloids of similar basicity, and the analytical 
settings are general and can be used for the analysis of a large group of diverse structures. Thus, 
we hope that many scientists may benefit by applying similar tools and strategies to other classes 
of alkaloids. While the described use of PDA spectra was specific for distinct classes of 
colchicinoids, other PDA spectra may serve as fingerprints for different alkaloid classes, and the 
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